Bortezomib + Cyclophosphamide + Dexamethasone + Isatuximab
Phase 1Active 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
AL Amyloidosis
Conditions
AL Amyloidosis
Trial Timeline
Apr 28, 2021 → Jul 24, 2026
NCT ID
NCT04754945About Bortezomib + Cyclophosphamide + Dexamethasone + Isatuximab
Bortezomib + Cyclophosphamide + Dexamethasone + Isatuximab is a phase 1 stage product being developed by Sanofi for AL Amyloidosis. The current trial status is active. This product is registered under clinical trial identifier NCT04754945. Target conditions include AL Amyloidosis.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04754945 | Phase 1 | Active |
Competing Products
20 competing products in AL Amyloidosis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ZN-d5 | Zentalis Pharmaceuticals | Phase 1/2 | 33 |
| VELCADE | Johnson & Johnson | Phase 1/2 | 41 |
| ABBV-383 (Etentamig) | AbbVie | Phase 1/2 | 41 |
| Venetoclax + Dexamethasone + Daratumumab | AbbVie | Phase 1/2 | 41 |
| Eplontersen Solution for Injection | AstraZeneca | Phase 1 | 33 |
| Treatment of transthyretin (ATTR) amyloidosis in observational study setting | AstraZeneca | Pre-clinical | 23 |
| Carfilzomib + Dexamethasone | Amgen | Phase 1 | 32 |
| Idelalisib | Gilead Sciences | Phase 2 | 51 |
| Tafamidis | Pfizer | Pre-clinical | 22 |
| Tafamidis | Pfizer | Pre-clinical | 22 |
| Fx-1006A | Pfizer | Phase 2 | 51 |
| tafamidis | Pfizer | Pre-clinical | 22 |
| Cyclophosphamide + Dexamethasone + Elotuzumab + Lenalidomide | Bristol Myers Squibb | Phase 2 | 51 |
| Isatuximab | Bristol Myers Squibb | Phase 2 | 51 |
| Bendamustine Hydrochloride + Isatuximab | Sanofi | Phase 2 | 51 |
| NC-503 (Anti-amyloidotic (AA) Agent) | GSK plc | Phase 2/3 | 64 |
| NTLA-2001 + Placebo | Regeneron Pharmaceuticals | Phase 3 | 76 |
| Linvoseltamab | Regeneron Pharmaceuticals | Phase 1/2 | 40 |
| ALN-TTR01 + Sterile Normal Saline (0.9% NaCl) | Alnylam Pharmaceuticals | Phase 1 | 30 |
| Patisiran | Alnylam Pharmaceuticals | Phase 3 | 74 |